Navigation Links
BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
Date:6/20/2011

rporation is responsible for marketing XIAFLEX® in Japan. More information about the Company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding BioSpecifics' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium Pharmaceuticals, Inc. ("Auxilium") regarding progress toward achievement of Auxilium's objectives for the US launch of XIAFLEX® for Dupuytren's contracture; the ability of Pfizer, Inc. to achieve its objectives for XIAPEX® in Europe; the ability of Asahi Kasei to achieve its objectives for XIAFLEX® in Japan; the success of the Phase 3 trials for XIAFLEX for the treatment of Peyronie's disease; the outcome of the dispute with Auxilium over the Company's right to conduct clinical trials; the Company's ability to restart the Chien-803 trial for injectable collagenase for the treatment of canine lipomas and the clinical success of that trial; the Company's ability to initiate and complete clinical trials in additional indications, all of which will determine the amount of milestone, royalty and sublicense income BioSpecifics may receive; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2010 and
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
2. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
3. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
4. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
5. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
6. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
7. BioSpecifics Technologies Corp. Amends Its Rights Agreement
8. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
10. BioSpecifics Technologies Corp. to Present at BioCentury Newsmakers in the Biotech Industry Conference
11. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 “Due ... cane,” said an inventor, from Gurnee, Ill. “While using the ... could be and I thought there needed to be a ... He invented the SPIKE BLOCK. , The SPIKE BLOCK offers ... doing so, it would help to reduce injuries and damage ...
(Date:11/22/2014)... In order to provide better services, LunaDress has updated ... The business knows that a suitable cocktail party dress is ... Now, the party dresses supplier’s high quality items are offered ... company in fashion industry, LunaDress understands that it is not ... it always raises the professional level and innovation ability. The ...
(Date:11/22/2014)... 22, 2014 "My friend went in ... by the machine," said an inventor from Cambria Heights, ... go back a second time because the first results ... She developed the patent-pending MAMO EASY to offer a ... design saves the patient from the pain normally involved ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication ... The article states that, “While they give off the appearance ... go into creating this powerful look.” , One of the ... choosing which kind of block matches your home environment and ... “The two main options are concrete and stone blocks. But ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2
... The Health Coalition on Liability and Access released a ... on the state and federal level. The report detailed ... passed laws limiting non-economic damages, while also acknowledging the ... to be enacted and is unlikely in the 111th ...
... are many targets now for interfering with the process , , ... from infected to uninfected immune system T-cells has been captured ... could lead to new ways to block the transmission of ... have focused on free- roaming viruses, but this study shows ...
... Test drives of the Simulated Impaired Driving Experience(R), (SIDNE(R)), ... be attending the Lifesavers conference at the Gaylord Opryland ... 30 and 31. The Lifesavers Conference is a national ... injuries on our nation,s roadways. "We are excited to ...
... Urged to Register with Safe and Well WASHINGTON, March 27 ... North Dakota and Minnesota today to staff shelters that will be ... levees as it rises to record heights. Projections are that the ... feet above flood stage, and the National Weather Service reports water ...
... 27 Zydus Pharmaceuticals announced today that it has ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... This product is available for immediate shipment.Topiramate tablets ... years old or older with partial onset or primary ...
... NYU School of Medicine have been named Early Career ... honorees, Iannis Aifantis, Ph.D. associate professor of pathology, co-director ... Cancer Institute and Jeremy S. Dasen Ph.D., assistant professor ... are among 50 of the nation,s top scientists being ...
Cached Medicine News:Health News:HCLA Releases Report on Status of Medical Liability Reform 2Health News:Scientists Capture HIV Transfer Among T-Cells on Video 2Health News:Innocorp, ltd. to Attend Lifesavers Conference 2Health News:Red Cross Readies Shelters As Flood Waters Threaten to Top Levees 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 2Health News:2 NYU scientists named Howard Hughes Medical Institute's Early Career Scientists 3
... CARDIAC proBNP assay is a rapid and accurate ... reader system assisting the diagnosis and assessment of ... is both speed and accuracy profit ... CARDIAC proBNP assay = 12 minutes. In emergency ...
The SJM Sguin annuloplasty ring, a semi-rigid ring, is constructed of a one-piece solid core of ultra-high-weight polyethylene enclosed in a knitted polyester sewing cuff....
Intermittent catheter...
... to a new dimension in vitreoretinal ... tool composed of purified perfluoro-n-octane, you ... Perfluoron is ideal for managing retinal ... retinal tears and trauma. , ,Certified ...
Medicine Products: